At high levels, host cell proteins (HCPs) can cause immunogenic responses and reduced efficacy of biologics, so it is imperative to have an effective, robust HCP assay to detect them and mitigate these effects. Challenging your HCP assay can improve risk mitigation and strengthen your HCP control strategy.
Download this whitepaper to discover answers to questions such as:- What is the major challenge of developing a generic HCP ELISA?
- Some HCPs are known to bind mAbs. How can we detect these HCPs using ELISA?
- What is a good target level of the final concentration of HCP?
